(ANSA) - ROME, JUNE 09 - Against chronic lymphatic leukemia, a new drug promises positive effects and an increase in survival without worsening the disease. The final results of the phase III Elevate-Rr study show a progression-free survival and fewer atrial fibrillation events with the use of diacalabrutinib than the currently used drug Ibrutinib. "One of the major obstacles to the treatment of patients with chronic lymphocytic leukemia, patients who generally receive diagnosis after age 70 and often have one or more comorbidities, is to find effective and tolerated treatment options for long-term management of the disease, without interrupting the treatment path - explains Paolo Ghia, professor of Medical Oncology at theVita-Salute SanRaffaele University - The results of the Elevate-Rr study confirm the potential of acalabrutinib in terms of disease control for patients with chronic lymphatic leukemia who have already faced a first line of treatment "." Having an effective and better tolerated therapeutic option represents a 'excellent news for clinicians and for the more than 3,000 patients in Italy who receive this type of diagnosis every year ", he adds.excellent news for clinicians and for the more than 3,000 patients in Italy who receive this type of diagnosis every year ", he adds.excellent news for clinicians and for the more than 3,000 patients in Italy who receive this type of diagnosis every year ", he adds.
Chronic lymphocytic leukemia (CLL) is the most common form of dileukemia in adults, with an estimated 191,000 new cases worldwide. (HANDLE).